Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
about
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancerSerum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma.Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinomaIntensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysisMetformin reduces serum CA199 levels in type 2 diabetes Chinese patients with time-effect and gender differenceUse of complementary and alternative medicine before and after organ removal due to urologic cancer.Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer.Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.Lymph node ratio and preoperative CA 19-9 levels predict overall survival and recurrence-free survival in patients with resected pancreatic adenocarcinoma.Modelling prognostic factors in advanced pancreatic cancerChange in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancerCombined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer.Pathologic response to preoperative therapy: does it mean what we think it means?Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients.Evaluation of vascular signal in pancreatic ductal carcinoma using contrast enhanced ultrasonography: effect of systemic chemotherapy.Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis.CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.Nucleosomes in pancreatic cancer patients during radiochemotherapy.Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update.Comparison of LUMIPULSE(®) G1200 With Kryptor and Modular E170 for the Measurement of Seven Tumor Markers.
P2860
Q30423279-67769F27-D5A9-4989-9034-0C77242D2CACQ33265964-18AF3146-328F-4C49-B81E-86614FE131ACQ33923018-264998F5-695B-471C-8A89-F4E54B4C058EQ34275247-F383EF1B-BCE6-485F-83A2-57D1F1606FF6Q34344188-F666A601-B6F2-4926-9D95-B26F8E2E20F2Q34636501-E238CA5F-B2FF-4366-A988-D8FB7D8A300DQ34732888-B234105E-E85E-4EAA-88E8-04801AF079BFQ34976612-A96CFA61-FE97-4597-B48F-34C6139F798AQ35064078-8B016F19-5294-49A7-830B-BA8AF59535A9Q36140554-E4FADCDD-3507-4362-91FF-0BA7A88978E3Q36561493-07BC2163-240D-4A08-BBE7-CFF5CCFBAEF4Q36614087-77E21ED8-B03F-4D30-9457-273438D0AB0AQ36637079-6F034238-5977-47C1-B3AB-C201A215FABFQ36882688-6C89D195-226B-42D1-88DD-161CCE64286CQ37285980-8D57EEA7-4869-47B4-B43C-09FE413A5E9EQ37295836-BF75AD33-BB8C-4556-880C-EA6CAF514771Q37339612-30162C73-4BD7-437A-8096-5D4C13A64632Q37424918-E0797399-4B6A-409B-9B17-28AA83A35B2FQ41963194-8D921C91-D2FB-4517-989F-4F74C769662EQ42375843-740F97CE-5A9C-4BBF-B3E5-A39FE470A495Q43004302-2D715A92-D815-4EEF-9306-FE8284F09978Q45404222-DCC7C167-7981-442D-99C6-53490B4AE6E3Q46194311-9C05FD8D-3801-4B41-B65D-FFC41D9242EAQ46365876-D4218241-0AE6-4A50-B50C-962457E16E8DQ51081555-E0F5F652-C9A2-4E10-857B-2A5A9185A0D7Q53155763-E39C333B-75F2-42D1-ACFB-2F47A374D478
P2860
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Predictive value of carbohydra ...... reated with radiochemotherapy.
@en
Predictive value of carbohydra ...... reated with radiochemotherapy.
@nl
type
label
Predictive value of carbohydra ...... reated with radiochemotherapy.
@en
Predictive value of carbohydra ...... reated with radiochemotherapy.
@nl
prefLabel
Predictive value of carbohydra ...... reated with radiochemotherapy.
@en
Predictive value of carbohydra ...... reated with radiochemotherapy.
@nl
P2093
P1476
Predictive value of carbohydra ...... reated with radiochemotherapy.
@en
P2093
Alexander F deVries
Eckehard Horst
Frank Bruns
John W Hausler
Normann Willich
Oliver Micke
Rene Kurowski
Ulrich Schäfer
P356
10.1016/S0360-3016(03)00524-8
P407
P577
2003-09-01T00:00:00Z